By Suherman Candra Maholtra 
New clinical research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) indicates that individuals living with established heart disease who receive a shingles vaccine experience nearly half the rate of serious cardiovascular complications within a year compared to those who remain unvaccinated. The study, which analyzed a massive cohort of nearly a quarter-million American adults, suggests that the preventive benefits of the herpes zoster vaccine extend far beyond the dermatological and neurological protections for which it was originally designed. By reducing the incidence of shingles outbreaks, the vaccine appears to mitigate a potent trigger for systemic inflammation and blood clotting, both of which are primary drivers of heart attacks and strokes.
The findings come at a time when the medical community is increasingly investigating the intersection of infectious diseases and chronic vascular conditions. While the shingles vaccine has long been recommended for adults over the age of 50 to prevent a painful, blistering rash and the potential for long-term nerve damage, this new data positions the immunization as a critical component of secondary prevention for patients already diagnosed with cardiovascular disease.
Understanding the Study Methodology and Patient Demographics
To evaluate the potential cardioprotective effects of the shingles vaccine, researchers utilized TriNetX, a comprehensive global health research network that provides access to de-identified electronic medical records from millions of patients across the United States. The study specifically targeted a high-risk demographic: adults aged 50 and older who had already been diagnosed with atherosclerotic cardiovascular disease (ASCVD). This condition, characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls (plaque), is the leading cause of heart-related morbidity and mortality worldwide.
The research team identified a total of 246,822 patients who met the inclusion criteria between the years 2018 and 2025. To ensure a rigorous comparison, the researchers employed a propensity score matching technique. This allowed them to create two equal groups of 123,411 individuals. One group had received at least one dose of a shingles vaccine—either the older live-attenuated Zostavax or the newer, more common recombinant Shingrix—while the other group remained unvaccinated.
The two cohorts were meticulously matched based on a wide array of variables to eliminate confounding factors. These included age, gender, ethnicity, and pre-existing health conditions such as hypertension, diabetes, and chronic kidney disease. Furthermore, the researchers adjusted for socioeconomic determinants of health, including housing stability, employment status, education levels, and literacy, to account for the "healthy user bias"—the tendency for people who seek vaccines to also engage in other health-promoting behaviors.
Substantial Risk Reductions Across All Cardiac Measures
The primary focus of the analysis was the occurrence of major adverse cardiac events (MACE) within a one-year follow-up period, starting one month after the date of vaccination. The results revealed a stark contrast between the two groups. Vaccinated individuals were 46% less likely to experience a major adverse cardiac event than their unvaccinated counterparts.
When the data was broken down into specific outcomes, the protective trend remained consistent:
- All-Cause Mortality: The vaccinated group saw a 66% reduction in the risk of death from any cause during the study period.
- Heart Attack (Myocardial Infarction): The risk of suffering a heart attack was 32% lower among those who received the vaccine.
- Stroke: Vaccinated patients experienced a 25% reduction in the incidence of stroke.
- Heart Failure: The risk of developing or experiencing an exacerbation of heart failure dropped by 25%.
Dr. Robert Nguyen, a resident physician at the University of California, Riverside and the study’s lead author, emphasized the magnitude of these figures. According to Dr. Nguyen, the 46% reduction in MACE is a "substantial" finding that rivals the benefits typically seen from aggressive lifestyle interventions, such as smoking cessation or the commencement of high-intensity statin therapy.
The Biological Link: Why a Virus Vaccine Protects the Heart
The biological rationale for these findings lies in the relationship between viral reactivation and systemic inflammation. Shingles is caused by the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissues near the spinal cord and brain. Decades later, particularly as the immune system weakens with age or stress, the virus can reactivate as shingles.
Recent medical literature has established that a shingles outbreak is not merely a skin condition; it is a systemic inflammatory event. When VZV reactivates, it replicates within the blood vessel walls (vasculopathy), leading to inflammation and structural changes in the arteries. This inflammation can cause the rupture of pre-existing atherosclerotic plaques. When a plaque ruptures, the body’s clotting mechanism kicks in, which can lead to a sudden blockage of blood flow to the heart or brain.
Furthermore, shingles infections have been shown to trigger a "pro-thrombotic state," where the blood is more likely to form clots. Previous studies have indicated that the risk of stroke and heart attack is significantly elevated in the weeks and months immediately following a shingles episode. By preventing the reactivation of the virus, the vaccine effectively removes a significant physiological stressor that could otherwise lead to a catastrophic cardiovascular event.
Contextualizing the Findings Within the ACC.26 Scientific Session
The presentation of this study at the American College of Cardiology’s Annual Scientific Session (ACC.26) places the research at the center of the global conversation on cardiology. The ACC meeting is one of the most prestigious gatherings of cardiovascular professionals in the world, where new guidelines are often debated and clinical practice is shaped.
The study, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," was scheduled for presentation on Monday, March 30, in the poster sessions at Hall E. The timing is notable, as it follows a string of recent studies exploring the "pleiotropic" effects of vaccines—benefits that go beyond the primary target of the immunization. For instance, the influenza vaccine and the COVID-19 vaccine have both been linked to reduced rates of heart attacks in high-risk populations. This shingles research adds a powerful new chapter to that body of evidence.
Implications for Public Health and Clinical Practice
The Centers for Disease Control and Prevention (CDC) currently recommends two doses of the recombinant shingles vaccine (Shingrix) for adults aged 50 and older. It is also recommended for adults 19 and older who have weakened immune systems due to disease or therapy. Despite these clear guidelines, vaccine uptake remains suboptimal in many regions, often due to a lack of awareness or general vaccine hesitancy.
Dr. Nguyen noted that these results provide clinicians with a new, evidence-based argument to encourage vaccination among their heart patients. "Vaccines are one of the most important medicines we have to prevent disease," he stated. "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine."
From a public health perspective, the potential cost savings are immense. Cardiovascular disease is the most expensive diagnostic group in the U.S. healthcare system. If a simple two-dose vaccine can reduce major cardiac events by nearly half in a high-risk population, the reduction in hospitalizations, emergency surgeries, and long-term disability could save billions of dollars annually, while simultaneously improving the quality of life for millions of seniors.
Limitations and the Need for Long-Term Data
While the study’s results are compelling, researchers have acknowledged certain limitations. The primary analysis focused on the first year following vaccination. While this provides a snapshot of immediate benefit, it does not fully address the longevity of the cardioprotective effect. However, Dr. Nguyen pointed to a 2025 study which suggested that the cardiovascular benefits of the shingles vaccine could persist for up to eight years in generally healthy populations, though the effect size was smaller (around 23%) than that seen in this specific high-risk ASCVD cohort.
Additionally, as an observational study using electronic health records, it cannot definitively prove a cause-and-effect relationship in the same way a randomized controlled trial (RCT) would. Even with the rigorous propensity score matching, there remains the possibility of unmeasured confounding factors. For example, individuals who choose to be vaccinated may be more likely to adhere to their prescribed heart medications or follow a heart-healthy diet.
Conclusion: A New Frontier in Preventive Cardiology
The research presented at ACC.26 marks a significant milestone in our understanding of how infectious disease prevention intersects with chronic disease management. For the millions of Americans living with atherosclerotic heart disease, the shingles vaccine may no longer be viewed as an "optional" immunization for skin health, but as a vital tool for cardiovascular survival.
As the medical community continues to digest these findings, the focus will likely shift toward integrating vaccination checks into standard cardiac care protocols. By treating the shingles vaccine as a "cardioprotective" intervention, similar to prescribing an aspirin or a statin, healthcare providers may be able to significantly lower the burden of heart disease in the aging population. The study serves as a potent reminder that in the complex ecosystem of the human body, protecting one system—the immune system—can have profound and life-saving implications for another—the heart.
